Clinical trial
A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin
NCT02810457 is registered in ClinicalTrials.gov with Centus Biotherapeutics Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin
- Lead sponsor
- Centus Biotherapeutics Limited
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 7, 2016
- Completion date
- January 26, 2022
- Enrollment
- 731 (actual)
- Sites
- 147
Conditions
As the registry lists them; a condition with its own page is linked.